ArticleMikrochimica acta2026
Urease-driven nanomotors loaded with sorafenib for magnetically-guided accumulation and deep tissue penetration towards hepatocellular carcinoma therapy via ferroptosis induction.
Article in Mikrochimica acta, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Targeting ferroptosis induction via nanomaterials in hepatocellular carcinoma: an insight into mechanism and therapeutic potential.Journal of nanobiotechnology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Hepatocellular carcinoma (HCC), accounting for 75-85% of liver cancers, faces limited therapeutic efficacy due to late-stage diagnosis, high malignancy, and poor drug permeability. Sorafenib (SF), a first-line multi-kinase inhibitor for unresectable HCC, suffers from low tumor-targeting efficiency and adverse effects. This study proposes a urease-driven nanomotor system (CUNMs + SF) to enhance SF delivery and tumor penetration. The nanomotors utilize porous magnetic silica nanoparticles (PMSNs) loaded with SF and modified with cyclodextrin-urease hybrids. This design enables magnetic targeting to HCC sites and autonomous propulsion via urea-fueled enzymatic conversion, overcoming physiological barriers in the tumor microenvironment.The system exhibits pH-responsive drug release (triggered at pH < 6.5) and induces ferroptosis in HCC cells by inhibiting the SLC7A13/GSH/GPX4 pathway, effectively suppressing tumor growth. In vitro and in vivo experiments demonstrate superior tumor accumulation, deep tissue penetration, and enhanced therapeutic outcomes compared to conventional SF. This work pioneers the application of enzyme-powered nanomotors in HCC therapy, addressing the limitations of systemic drug delivery while leveraging tumor-specific biochemical cues. The findings highlight the potential of biohybrid nanomotors for targeted cancer treatment and inspire future developments in stimuli-responsive nanomedicine for challenging malignancies.
Indexed as
Identifiers
41586895What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.